Centessa Pharmaceuticals Plc Stock Investor Sentiment
| CNTA Stock | USD 17.60 0.30 1.73% |
About 58% of all Centessa Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Centessa Pharmaceuticals PLC suggests that some traders are interested. The current market sentiment, together with Centessa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Centessa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Centessa |
Centessa Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Centessa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Centessa Pharmaceuticals that are available to investors today. That information is available publicly through Centessa media outlets and privately through word of mouth or via Centessa internal channels. However, regardless of the origin, that massive amount of Centessa data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Centessa Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Centessa Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Centessa Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Centessa Pharmaceuticals alpha.
Centessa Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 25000 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 15.0 subject to Rule 16b-3 | 09/09/2024 |
2 | Disposition of 16619 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 15.6883 subject to Rule 16b-3 | 09/25/2024 |
3 | Nantahala Capital Management LLC Buys Shares of 450,000 Centessa Pharmaceuticals plc - MarketBeat | 10/01/2024 |
4 | Disposition of 22205 shares by Saha Saurabh of Centessa Pharmaceuticals at 15.801 subject to Rule 16b-3 | 10/21/2024 |
5 | Disposition of 30203 shares by Saha Saurabh of Centessa Pharmaceuticals at 15.6663 subject to Rule 16b-3 | 10/22/2024 |
6 | Disposition of 2592 shares by Saha Saurabh of Centessa Pharmaceuticals at 15.3151 subject to Rule 16b-3 | 10/23/2024 |
7 | Disposition of 11742 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 15.3831 subject to Rule 16b-3 | 10/25/2024 |
8 | Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update | 11/12/2024 |
9 | Disposition of 32023 shares by Saha Saurabh of Centessa Pharmaceuticals at 18.2812 subject to Rule 16b-3 | 11/13/2024 |
10 | Is Centessa Pharmaceuticals Using Debt Sensibly | 11/14/2024 |
11 | Guggenheim lifts Centessa Pharma stock target, keeps buy on developments | 11/15/2024 |
12 | Disposition of 3511 shares by Saha Saurabh of Centessa Pharmaceuticals at 18.2365 subject to Rule 16b-3 | 11/21/2024 |
13 | Centessa Pharmaceuticals Shares Down 4.5 percent Time to Sell | 11/22/2024 |
14 | Centessa Pharmaceuticals CEO Saha Saurabh sells 5,450 in shares | 11/27/2024 |
Complementary Tools for Centessa Stock analysis
When running Centessa Pharmaceuticals' price analysis, check to measure Centessa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Centessa Pharmaceuticals is operating at the current time. Most of Centessa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Centessa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Centessa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Centessa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |